SYNTHESIS, ANTICANCER AND ANTIBACTERIAL ACTIVITY OF MALONIC ACID BISISATIN HYDRAZONES

*Bairy Padma, ¹Talluri Chandu, ²Kusuma Praveen Kumar

¹Department of Pharmaceutical Chemistry and Pharmaceutics, Sree Nagarjuna College of Pharmacy, Kadipikonda, Hanumakonda (M), Warangal, Andhra Pradesh, India – 506 003.
²Vaagdevi Institute of Pharmaceutical Sciences, Bollikunta, Warangal, Andhra Pradesh, India -506002.

Abstract

Malonic Acid Bisisatin Hydrazones (VIa-i) have been synthesized by the condensation of malonohydrazide (V) with corresponding isatin derivatives (III) in alcohol. The intermediate malonohydrazide (V) was prepared by the reaction of diethylamalonate (IV) with hydrazine hydrate. All the title compounds (VI) were screened for anticancer activity using HBL-100 cell lines by MTT method and antibacterial activity against *B. subtilis*, *S. aureus*, *E. coli* and *P. vulgaris*. The structures of newly synthesized compounds were established on the basis of elemental analysis, IR, ¹H NMR and mass spectral data.

Key words: Isatin, Anticancer Activity, Antibacterial Activity.

Introduction

Isatin hydrazones belong to an important class of heterocyclic compounds in medicinal chemistry associated with wide range of biological activities such as antimicrobial activity (Pandeya et al., 2005), antiviral activity (Beauchard et al., 2006), antineoplastic activity and CNS activity (Knockaert et al., 2002). The biological importance of the compounds inspired us to synthesize some new bisisatin hydrazones to get more potent compounds and screen for anticancer activity by the MTT method (Krief et al., 2005) and antibacterial activity by cup plate method (Seely et al., 1975). Synthesis of malonic acid bisisatin hydrazones (VIa-j) is shown in Scheme 1.

Materials and Methods

Melting points were determined in open capillary tubes, using Toshniwal melting point apparatus and are uncorrected. IR spectra were recorded on Perkin – Elmer spectrum BX-I series, FTIR spectrophotometer using KBr discs. PMR spectra were recorded on Brucker spectrosopin 400 MHz spectrophotometer using TMS as an internal standard. Purity was checked by TLC using TLC aluminum sheets silica gel 60, supplied by E.Merk, Mumbai, India. The spots were located by keeping the plate in iodine vapor and 2,4,5-trichlorobenzamine was supplied by S. D. Fine Chem Ltd, Mumbai, India.
Malonohydrazide (V) was prepared by refluxing, diethylmalonate (IV) in alcohol with hydrazine hydrate for 15 min. The progress of reaction and purity were routinely checked on TLC. The resultant white crystalline solid was filtered, washed with cold alcohol. The product was dried and recrystallized from ethanol (90%). m.p. 153°C and Yield 90%. Elemental Analysis found: C, 27.21; H, 6.12; N, 42.44; O, 24.23. Calculated for C₁₀H₈N₂O₂: C, 27.27; H, 6.10; N, 42.41; O, 24.22.

N₁,N₃-bis(2-oxindolin-3-ylidene)malonohydrazide (VI) by following method (Joaquim et al., 2001), the malonohydrazide (V, 0.01 mol) was added to an appropriate isatin (III, 0.02 mol) in ethanol (95%, 20 ml), and refluxed for 3-4 hours. The product obtained was filtered and washed repeatedly, with small portions of cold ethanol to remove the un-reacted isatins and hydrazide. The product was dried and purified by using column chromatography. The purity of the compound was checked by TLC. The compounds thus obtained were characterized as bisisatin malonohydrazide (VI) by their physical (Table 1) and spectral data.

N₁,N₃-bis(2-oxindolin-3-ylidene)malonohydrazide (VIa)
IR (KBr) (cm⁻¹): 1545 (C=N), 1690 (C=O), 3198 (NH).¹ 
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 8H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 391.11 (M+1).

N₁,N₃-bis(5-fluoro-2-oxindolin-3-ylidene)malonohydrazide (VIb)
IR (KBr) (cm⁻¹): 1566 (C=N), 1720 (C=O), 3248 (NH).¹ 
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.8 (m, 6H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 427.09 (M+1).

N₁,N₃-bis(5-chloro-2-oxindolin-3-ylidene)malonohydrazide (VIc)
IR (KBr) (cm⁻¹): 1556 (C=N), 1705 (C=O), 3235 (NH).¹ 
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 6H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 460.03 (M+1).

N₁,N₃-bis(5-bromo-2-oxindolin-3-ylidene)malonohydrazide (VID)
IR (KBr) (cm⁻¹): 1550 (C=N), 1694 (C=O), 3184 (NH).¹ 
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 6H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 549.92 (M+1).

Scheme 1: Synthesis of malonic acid bisisatin hydrazones

N₁,N₃-bis(5-methyl-2-oxindolin-3-ylidene)malonohydrazide (VId)
IR (KBr) (cm⁻¹): 1530 (C=N), 1690 (C=O), 3198 (NH).¹ 
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 2.5 (s, 6H, CH₃), 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 6H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 419.14 (M+1).

N₁,N₃-bis(5-nitro-2-oxindolin-3-ylidene)malonohydrazide (VII)
IR (KBr) (cm⁻¹): 1339 (NO₂), 1556 (C=N), 1702 (C=O), 3227 (NH).¹ 
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 6H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 481.08 (M+1).

N₁,N₃-bis(5-hydroxy-2-oxindolin-3-ylidene)malonohydrazide (VII)
IR (KBr) (cm⁻¹): 2985 (OH), 1632 (C=O), 3168 (NH).¹ 
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 6H, Ar-H), 9.6 (s, 2H, OH), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 423.10 (M+1).
N1-(5-chloro-2-oxoindolin-3-ylidene)-N3-(5-fluoro-2-oxoindolin-3-ylidene)malonohydrazide (VIh)  
IR (KBr) (cm⁻¹): 1560 (C=N), 1706 (C=O), 3205 (NH).  
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 6H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 444.06 (M+1).  
N1-(5-bromo-2-oxoindolin-3-ylidene)-N3-(5-fluoro-2-oxoindolin-3-ylidene)malonohydrazide (VIi)  
IR (KBr) (cm⁻¹): 1545 (C=N), 1656 (C=O), 3180 (NH).  
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 6H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 488.01 (M+1).  
N1-(5-bromo-2-oxoindolin-3-ylidene)-N3-(5-chloro-2-oxoindolin-3-ylidene) malonohydrazide (VIj)  
IR (KBr) (cm⁻¹): 1515 (C=N), 1676 (C=O), 3181 (NH).  
H-NMR (DMSO-d₆, 400 MHz), δ (ppm): 3.22 (s, 2H, CH₂), 6.8-7.9 (m, 6H, Ar-H), 10.80 (s, 2H, NHCO), 11.4 (s, 2H, NH indole). LC-MS (m/z): 504.98 (M+1).

**Antimicrobial Activity**  
The antimicrobial activity of all the newly synthesized compounds were determined by well plate method in nutrient agar (Hi-Media) was used for antibacterial activity. The antibacterial activity of the test compounds was assayed against *Bacillus subtilis*, *Staphylococcus aureus* (gram – positive) and *Escherichia coli* and *Proteus vulgaris* (gram – negative) by CUP-plate method.  
The compounds were tested at a concentration of a 100 µg/ml were prepared in dimethylformamide (DMF). The Petri dishes used for antibacterial screening were incubated at 37 ± 1º for 24 h; the diameters of zone of inhibition (mm) surrounding each of the wells were recorded. The results were compared with Ampicillin of a 50 µg/ml concentration and the screening results were presented in Table 2.

**Anticancer Activity**  
Malonic acid bisisatin hydrazones were subjected to *in vitro* MTT [3-(4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium Bromide] assay to detect cytotoxic antitumor property and *in vivo* test using tumor mouse model to detect noncytotoxic antitumor property were used. MTT assay was used for *in vitro* cytotoxic test and was performed as per the method of Alley et al. Cells were harvested from experimental-phase maintenance cultures. Four hundred cells were counted by trypan blue exclusion and dispensed within triplicate 96-well culture plates in 100 µl volumes for each venom concentration (Alley et al., 1988). The assay at each concentration was repeated twice. The cell proliferation activity was qualified on HBL-100 (ICLC NO. HTL 00004)- breast myoepithelial tumor cell line, by using Cisplatin as a standard. The results are represented in Table.2.

**Table 1:** Physical data of malonic acid bisisatin hydrazones

<table>
<thead>
<tr>
<th>Compound</th>
<th>R</th>
<th>R₁</th>
<th>Mol. Formula</th>
<th>Melting Point (°C)</th>
<th>Yield (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIa</td>
<td>H</td>
<td>H</td>
<td>C₁₉H₁₄N₆O₄</td>
<td>265-268</td>
<td>72</td>
</tr>
<tr>
<td>VIb</td>
<td>F</td>
<td>F</td>
<td>C₁₉H₁₂F₂N₄O₄</td>
<td>272-276</td>
<td>68</td>
</tr>
<tr>
<td>VIc</td>
<td>Cl</td>
<td>Cl</td>
<td>C₁₉H₁₂Cl₂N₄O₄</td>
<td>228-232</td>
<td>74</td>
</tr>
<tr>
<td>VId</td>
<td>Br</td>
<td>Br</td>
<td>C₁₉H₁₂Br₂N₄O₄</td>
<td>280-283</td>
<td>78</td>
</tr>
<tr>
<td>Vle</td>
<td>CH₃</td>
<td>CH₃</td>
<td>C₂₁H₁₈N₆O₄</td>
<td>269-273</td>
<td>66</td>
</tr>
<tr>
<td>VIe</td>
<td>NO₂</td>
<td>NO₂</td>
<td>C₁₉H₁₂N₂O₈</td>
<td>231-234</td>
<td>58</td>
</tr>
<tr>
<td>VIf</td>
<td>OH</td>
<td>OH</td>
<td>C₁₉H₁₂N₂O₈</td>
<td>221-223</td>
<td>66</td>
</tr>
<tr>
<td>VIh</td>
<td>F</td>
<td>Cl</td>
<td>C₁₉H₁₂ClF₆N₄O₄</td>
<td>268-271</td>
<td>72</td>
</tr>
<tr>
<td>VIi</td>
<td>F</td>
<td>Br</td>
<td>C₁₉H₁₂BrF₆N₄O₄</td>
<td>278-282</td>
<td>61</td>
</tr>
<tr>
<td>VIj</td>
<td>Cl</td>
<td>Br</td>
<td>C₁₉H₁₂BrClN₄O₄</td>
<td>241-243</td>
<td>63</td>
</tr>
</tbody>
</table>
Table 2: Anticancer and antibacterial activity of malonic acid bisisatin Hydrazones (VI)

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cytotoxic activity IC(_{50}) (µM)</th>
<th>Antibacterial activity (Zone of inhibition in mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>B. Subtilis</td>
</tr>
<tr>
<td>VIa</td>
<td>78</td>
<td>16</td>
</tr>
<tr>
<td>VIb</td>
<td>101</td>
<td>08</td>
</tr>
<tr>
<td>VIc</td>
<td>42</td>
<td>20</td>
</tr>
<tr>
<td>VId</td>
<td>56</td>
<td>15</td>
</tr>
<tr>
<td>VIe</td>
<td>31</td>
<td>10</td>
</tr>
<tr>
<td>VIf</td>
<td>152</td>
<td>15</td>
</tr>
<tr>
<td>VIg</td>
<td>66</td>
<td>17</td>
</tr>
<tr>
<td>VIh</td>
<td>96</td>
<td>11</td>
</tr>
<tr>
<td>VIi</td>
<td>171</td>
<td>06</td>
</tr>
<tr>
<td>VIj</td>
<td>135</td>
<td>--</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>25</td>
<td>NA</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>NA</td>
<td>22</td>
</tr>
</tbody>
</table>

Results and Discussion

The title compounds were obtained in good yields and purity. All the test compounds at the conc. of 20 µg/ml, 80 µg/ml, 100 µg/ml and 200 µg/ml were taken to evaluate the anticancer activity against HBL-100 cell lines and the results are presented as IC\(_{50}\) values. All the compounds showed anticancer activity in the range of 31 µM to 171 µM. The structure activity studies reveal that among the test compounds, the compound VIe with methyl substitution at C-5 position on indolinone moiety showed relatively high degree of anticancer activity with IC\(_{50}\) of 31 µM. The compounds, VIc, VId, VIg was next in the order of anticancer activity with IC\(_{50}\) values of 42 µM and 56 µM, 66 µM respectively. The results are statistically significant and the activity of the compounds is compared with the standard Cisplatin.

The test compounds showed mild antibacterial activity at the concentration of 100 µg/disc against gram-positive organism (B. subtilis, S. aureus) and gram negative (E. coli, P. vulgaris) organisms. The compound VIc was more active among all the test compounds followed by compound Vic, VIg, VId.

Acknowledgments

The authors are thankful to the Director and Principal, Sree Nagarjuna College of Pharmacy, Warangal, for providing laboratory facilities and financial support.

References


Seely HW, Van Demark PJ. Microbes in action: A laboratory manual of Microbiology, Mumbai: DB Taraporewala Sons and Co; 1975.55.